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Ischemic renal diseases: New insights into old entities. Vascular nephrop-
athies are a steadily increasing cause of end-stage renal failure. Arterio-
nephrosclerosis and arteriolonephrosclerosis are common features in the
hypertensive patient. This is especially true for blacks of African descent,
in whom hypertension and nephrovasculopathies are a major cause of
renal insufficiency. That primary hypertension leads to renal vascular
lesions, glomerular obsolescence and interstitial fibrosis has long been
established. It should not, however, obscure the fact that renal vascular
lesions can be observed in animal models as well as in some humans,
especially young blacks, in the absence of, or anticipating the onset of
hypertension. This leads to considering the hypothesis that nephroangio-
sclerosis might stem from a genetic defect in the renal vascular bed and
that this defect is strongly associated with the hypertensive trait. Athero-
sclerotic renal disease is a major, potentially treatable cause of chronic
renal failure, especially in whites. It leads to renal atrophy, but the
ischemic kidney retains a vigorous potential for tubular cell regeneration,
which pleads for early recognition and treatment. Recent data suggest that
renal ischemia, be it due to renal artery stenosis or to cholesterol crystal
embolism, ranks among the multiple causes of secondary focal segmental
glomerulosclerosis. Irrespective of its initial mechanism, ischemia induces
renal fibrosis, the pathophysiology of which is centered on increased
generation of angiotensin II. Finally, renal vascular lesions are commonly
observed in the course of various nephropathies, even in the absence of
hypertension, and the relationship between these lesions and the unfavor-
able prognosis of glomerulopathies, especially primary focal-segmental
glomerulosclerosis, membranous glomerulopathy and IgA glomerulone-
phritis, remains to be elucidated. Expanding knowledge of the spectrum of
nephrovasculopathies opens perspectives for investigating, understanding
and treating a major mechanism of progressive renal insufficiency.
Vascular nephropathies are a steadily increasing cause of
end-stage renal failure in the Western world. It has been
seven decades since Fahr and Volhard coined the term
“nephrosclerosis,” which they considered the consequence
of a primary sclerosis of the renal vessels, secondarily
complicated by hypertension. With the passage of time the
wheel turned full circle: nephrosclerosis was the conse-
quence of hypertension. However, recent epidemiologic,
genetic and clinical data suggest that in some instances
renal vascular lesions may precede hypertension or develop
without a rise in blood pressure. Likewise, various nephrop-
athies comprise renal vascular lesions that are not neces-
sarily accompanied by hypertension. Hence, most renal
diseases have an ischemic component accompanied by
renal fibrosis, and ischemia runs through the whole story of
fibrogenesis leading to end-stage renal failure.
In the 1980s, a few cases of captopril-induced renal
insufficiency in patients with atherosclerotic renal artery
stenoses disclosed the encouraging prospect of reversing
chronic renal failure in the azotemic patient resistant to
therapy. Since then, the concern of renal physicians about
nephron protection from ischemia has increased in inverse
proportion to their concern for renovascular hypertension.
Meanwhile, cholesterol embolism, a dreaded complication
of atherosclerosis, elicited a new flurry of pessimistic
publications.
The topic suggested by the Editor is a challenge, and a
stimulating one. It led us to some discussions that did not
always follow the beaten path. Our aim in this review is to
draw attention to selected aspects of nephrovasculopathies
and to open perspectives on a paramount mechanism of
developing renal insufficiency.
NEPHROANGIOSCLEROSIS
“Nephrosclerosis” was the term coined by Fahr [1] to
qualify the “renal hardening” that accompanies hyperten-
sion. Volhard, in a treatise on Bright’s disease [2], intro-
duced the section “Die Sklerosen” with “. . . die dritte
monosymptomatische Form . . . , welche sich klinisch durch
Hypertonie und Herzhypertrophie, anatomisch durch eine
prima¨re Sklerose der Nierengefa¨be auszeichnet” [. . . the
third, monosymptomatic form (of renal sclerosis) is char-
acterized clinically by hypertension and cardiac hypertro-
phy, and anatomically by a primary sclerosis of the renal
vessels]. However, for decades it has been considered that
hypertension is the cause rather than the consequence of
renal vascular injury [3], and it was shown that, indeed,
hypertension is highly deleterious to the renal vascular bed
[4, 5]. Nevertheless, the notion that renal vascular lesions
can be separated from hypertension in animal models, that
the same can occasionally occur in humans, and that in a
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host of nephropathies renal vascular lesions are not neces-
sarily accompanied by hypertension justifies further delib-
eration on this time-honored concept.
The lesions of nephroangiosclerosis involve all the renal
structures in a fibrous kidney
Benign nephro(angio)sclerosis involves not only the preglo-
merular vessels, that is, arcuate arteries, interlobular arter-
ies and glomerular afferent arterioles, but all kidney struc-
tures [4, 6, 7]. Arteries show intimal thickening by
myofibroblasts (“synthetic state smooth muscle cells”) and
dense collagen tissue. Elastic laminae are reduplicated. The
media is initially thicker than normal, before undergoing
atrophy. The vascular lumen is narrowed. These lesions
seem to be the consequence of high blood pressure more
than of aging [8]. Arteriolohyalinosis, although common
and often found early in life, is not necessarily a feature of
nephroangiosclerosis. Nevertheless, this lesion is more se-
vere in primary hypertension [5], and its severity is corre-
lated with coronary artery disease [9]. Arteriolosclerosis of
the afferent arteriole is the most ominous. It is correlated
with the degree of hypertension, male gender and aging [5,
8]. It is paramount in inducing functional and morphologic
ischemic lesions of the glomerulus, including GFR impair-
ment and focal or global glomerulosclerosis [7]. Extravas-
cular lesions resemble chronic interstitial nephritis [10].
The fibrotic interstitium is interspersed with inflammatory
cells. Atrophic and microcystic tubules containing hyaline
casts give the appearance of “pseudothyroid areas.” Isch-
emic glomeruli undergo tuft retraction, basement mem-
brane folding and thickening of Bowman’s capsule. Numer-
ous glomeruli are sclerotic. Some are obsolescent, which
can be due to simple ischemic global sclerosis, or the
consequence of focal and segmental glomerulosclerosis
which is a common stage in the development of hyperten-
sive glomerulopathy (p. 1208 in [7]). This is discussed
below. Glomerular obsolescence may also be the conse-
quence of overlooked episodes of malignant hypertension.
The kidney is not always small. Radiologically, its con-
tours may be smoothly scalloped, indicating segmental
ischemic fibrous atrophy [11]. For the renal pathologist,
cortical scalloping reflects ischemic atrophy resulting from
lesions in the larger arteries (arterionephrosclerosis). If the
patient has been hypertensive over a prolonged period, the
cortical surface is granular, reflecting arteriolar disease
(arteriolonephrosclerosis). The two may obviously coexist.
Nephroangiosclerosis is especially common in blacks
Nephroangiosclerosis has been widely studied in the U.S.
[12], especially in blacks [13]. An increasing cause of
end-stage renal disease (ESRD) in the U.S. and in Europe
[14, 15], nephroangiosclerosis closely follows the incidence
of hypertension in blacks of African ancestry [16, 17]. Their
propensity to develop hypertension and nephroangioscle-
rosis is probably the consequence of environmental factors
[18] and various intermediate phenotypes [16], but also of
a genetic trait favoring fibrosis in various tissues [19].
Hypertensive ESRD in African-Americans progressed
from 6.4 per 100,000 in 1974-1978 to 9.6 in 1982-1987 [20].
The corresponding numbers in Caucasians were only 0.36
and 0.62, and nephroangiosclerosis is considered an un-
common cause of developing chronic renal failure in whites
[21].
Tracy et al [22] compared renovasculopathies found on
coroner’s autopsies in three age groups of white and black
males aged 25 to 54 years. The difference between whites
and blacks was already present and well established in the
youngest group, 25 to 34 years of age. Autopsy specimens
were also studied [23] to assess the magnitude of early
nephroangiosclerosis in five different ethnic population
groupings. Blacks exceeded whites in the magnitude of
incipient nephroangiosclerosis in all age groups, from 15
through 24, to 45 through 54 years. Tracy and coworkers
concluded that the variation of blood pressure among
individuals is in part nephroangiosclerosis-linked at all ages
and all stages of blood pressure elevation. Although con-
clusions drawn from blood pressure readings made in
population surveys and matched with vascular lesions ob-
tained from autopsies could be debatable, the message
conveyed by the Tracy group points to the notion that
nephroangiosclerosis, especially in young blacks, antici-
pates the onset of hypertension later in life [24]. Patholo-
gists have long recognized the presence of fibrointimal
arterial lesions in normotensive patients whose kidneys are
removed for various causes, such as cancer. These lesions
become progressively more prominent with advancing age,
and their distribution suggests that they may represent a
compensatory response to loss of smooth muscle (Figs. 1
and 2). The concept that renal vascular lesions may precede
the onset of human hypertension deserves further discus-
sion.
Experimentally, hypertension does not necessarily
precede nephroangiosclerosis
Most data on the arterial/arteriolar lesions accompanying
hypertension have been obtained in the 2 kidneys-1 clip
Goldblatt model of renovascular hypertension, and in the
spontaneously hypertensive rat (SHR). In the former, the
unclipped kidney is rapidly altered by arterial lesions of
malignant hypertension. Actually, the closest animal model
of human essential hypertension is the SHR, which exhibits
vascular lesions of nephroangiosclerosis, precipitated by a
sodium-rich diet, administration of DOCA or infusion of
angiotensin (Ang) II [25]. However, very few studies have
addressed the issue of renal vascular morphology in SHRs
made normotensive by treatment. In 1981 Feld et al [26]
undertook such a study. SHRs were maintained at normal
blood pressure to the age of 100 weeks by antihypertensive
drugs. Despite rigorous blood pressure control, they devel-
oped marked proteinuria and the lesions characteristic of
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hypertensive nephropathy. The authors concluded that
their findings spoke against the hypothesis of increased
intravascular pressure as the major factor in the pathogen-
esis of arteriolar sclerosis and rather favored a genetic
defect in the vascular system of the SHR, a defect strongly
associated with the hypertensive trait.
Later protocols confirmed that severe renal vascular
lesions are found in normo- or even hypotensive animals.
Smeda, Lee and Forrest [27, 28] studied the renal vessels in
a strain of hypertensive rats that normally has lesions of
nephroangiosclerosis. Antihypertensive therapy was admin-
istered to pregnant females, whose offspring were normo-
tensive at birth and were never hypertensive. However, they
exhibited renal vascular lesions, indicating that hyperten-
sion is not a prerequisite for vascular lesions and that
genetic hypertension and renal vascular lesions may con-
ceivably develop in parallel.
The role of the angiotensin converting enzyme (ACE)
gene in the morphogenesis of renal vessels in the mouse
was studied by Krege et al after gene knockout [29].
Although hypotensive, homozygous mice had thickened
and hypercellular renal vascular walls with a narrow lumen.
Kim et al produced mice with one to four copies of the
angiotensinogen gene [30]. Blood pressure was propor-
tional to the number of gene copies. Although mice with no
copy of the gene were hypotensive, they had considerable
renal vascular lesions, whereas the other, hypertensive mice
were spared. This study tended to indicate that angio-
tensinogen or angiotensin is necessary for developing nor-
mal renal vascularization, but also that hypertension is not
responsible for the renal vascular lesions observed in this
model. Niimura et al [31] examined renal tissue in a
hypotensive strain of mice homozygotic for a “nil” mutation
of the angiotensinogen gene. Three weeks after birth they
had renal cortical lesions of nephroangiosclerosis associ-
ated with hyperexpression of platelet-derived growth factor
B mRNA and of TGF-b1. These angiotensinogen-deficient
mice had very high intrarenal levels of renin and the
authors hypothesized that renin, rather than angiotensin,
could have a mitogenic effect on the renal vessel cells.
Transgenic models have adduced further evidence sup-
porting the concept of blood pressure-independent induc-
tion of renal vascular lesions. Hocher et al [32] transferred
the human endothelin-1 gene into the germline of mice.
The transgene was expressed predominantly in the brain,
lung and kidney. Blood pressure was not affected. Besides
glomerulosclerosis, interstitial fibrosis and cysts, an in-
creased media/lumen ratio was found in intrarenal arteries
in 14-month-old mice. Ve´niant et al [33] designed a model
of transgenic rats expressing prorenin exclusively in the
liver. Prorenin concentrations were increased 400-fold in
male rats, whereas plasma active renin concentration was
only slightly elevated. Blood pressure was similar in trans-
genic rats and in nontransgenic controls. However, renal
histology was consistent with moderate to severe nephroan-
giosclerosis, including arterial wall thickening, tubulointer-
stitial atrophy and inflammation, and glomerulosclerosis.
Non-renal vessels were also altered, with aortic wall hyper-
trophy and subendocardial and pericoronary fibrosis. This
experiment had a twofold interest: (1) to confirm the
foregoing data which all show that hypertension is not a
prerequisite for nephroangiosclerosis; and (2) to demon-
strate that long-term exposure to elevated prorenin is
vasculotoxic.
Fig. 1. Interlobular artery from a 37-year-old normotensive patient,
showing early lesions of arteriosclerosis. Where the media is the thickest
(left), the degree of intimal fibrosis is least. Conversely, progressing along
the vessel, the media thins out to a single cell layer and the intima becomes
much thicker, with a mixture of fibrosis and myofibroblasts. However, the
caliber of the lumen does not change appreciably from one region to the
other. The overall picture suggests that the intimal lesions are partially
compensatory for the medial atrophy (trichrome stain, 3260).
Fig. 2. Interlobular artery from an 85-year-old normotensive patient.
This artery shows the lesions seen in Figure 1, but in an exaggerated
fashion. Where the muscularis is the thickest (arrow), the intima is the
thinnest. To one side, however, the media thins out with frank aneurysm
formation and with marked compensatory thickening of the intima. The
lumen is actually wider in the region of the greatest intimal thickening
(trichrome stain, 3220).
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ATHEROSCLEROTIC RENAL DISEASE
Vascular surgeons showed as early as 1956 that revascular-
ization of atherosclerotic renal arteries might improve
renal function in the hypertensive patient [34]. However,
atherosclerosis remained long overlooked as a cause of
renal failure. In the 1980s it was established that athero-
sclerotic renal artery stenosis is a leading cause of renal
insufficiency, and that this condition ranks among the rare
etiologies of chronic renal failure amenable to improve-
ment or stabilization [35–43].
Ischemic renal disease, a major cause of potentially
treatable chronic renal failure
The prevalence of atherosclerotic renal disease is not
precisely established. Greco and Breyer [43] analyzed the
percentage of patients with .50% renal artery stenosis in
11 publications between 1975 and 1994. The results ranged
from 11 to 42%. Radiologically, in 824 patients, including
201 older than 60, renal artery stenoses were found in 5.5%
below, and in 16.4% above 60 years of age [44]. Three
studies in which a cardiac radiologic procedure was fol-
lowed by renal artery angiography showed atherosclerotic
plaques in 5% [45], 29% [46] and 15% [47], respectively.
Prevalence was 29% in case of coronary stenosis and 10%
when the coronaries were patent. Aortic angiography in
385 patients disclosed an aneurysm in 109, aorto-occlusive
disease in 21 and lower limb occlusive disease in 189
patients [38]. Renal artery stenosis was found in respec-
tively 38%, 33% and 39%. Prospective studies based on
duplex Doppler scanning in patients with diffuse athero-
sclerosis yielded 15% with renal artery involvement [48,
49]. Appel et al extrapolated to the whole U.S. population
the results of duplex scanning in hemodialysis patients: they
postulated that renal ischemia would be responsible for 7%
of end-stage renal disease and be the fourth cause of renal
failure leading to dialysis in the U.S. [42]. These numbers
illustrate the magnitude of the public health problem.
However, not all subsets of the population are similarly at
risk.
Atherosclerotic renal artery disease is rare in blacks [14,
50–52]. In patients with malignant hypertension its preva-
lence was 43% in whites and 7% in blacks [53]. A significant
white predominance was indicated by Appel et al [42].
Among 53 cases the black:white ratio was 21:32. In 45
thoroughly investigated patients, critical stenosis was noted
in 10, who were all white. Saklayen reviewed 12 papers on
renal cholesterol embolism published between 1960 and
1987, and of 43 patients, only one was black [54].
The consequences of critical renal artery stenosis are
functional and morphologic
Renal function impairment. In extreme ischemic condi-
tions collateral circulation may maintain renal viability [43,
55, 56]. Yet significant renal artery stenosis (.60 to 70%)
induces functional and morphological changes that are not
always reversible. Renal hypoperfusion impairs preglo-
merular pressure and flow, especially in the cortex [57].
Renin secretion with production of angiotensin II (Ang II)
follows reduced shear stress on the afferent arteriole. This
elicits vasoconstriction of the efferent arteriole and de-
creases production of prostacyclin and nitric oxide, which
normally blunt the effects of Ang II [58]. The efferent
arteriole is rich in Ang II receptors. Progressive vasocon-
striction of this vessel is essential to preserve the jeopar-
dized GFR [59]. This explains why the first publications on
atherosclerotic renal ischemia stemmed from observations
of acute renal failure following treatment with an ACE
inhibitor [60, 61]. Also important is the notion of “critical
perfusion pressure” [62] demonstrated with nitroprusside
infusion. In hemodynamically significant renal artery ste-
nosis, reducing blood pressure below a given level induces
a sudden drop in GFR. Thus, any antihypertensive drug is
liable to impair renal function in severe renal artery
stenosis when upstream pressure can no longer force blood
through the stenotic defile.
Renal tissue atrophy. Chronic hypoperfusion is usally
accompanied by renal atrophy, although normal kidneys
remain viable with blood flows and pressures below those
needed for glomerular filtration [55]. Thus, as less than
10% of oxygen delivery is required for kidney tissue
metabolism [63], chronic ischemia does not damage renal
tissue simply by the lack of red cell and oxygen supply, as
discussed below.
The poststenotic kidney shows a mixture of vascular
sclerosis, cholesterol crystals, tubular atrophy, interstitial
fibrosis and inflammatory cells, atubular glomeruli and
focal or global glomerulosclerosis [64]. These lesions differ
from the minor changes observed in pure ischemia follow-
ing fibromuscular renal artery stenosis in a young female.
They rather characterize what we had called “atheromatous
renal disease” [37], a combination of atherosclerosis, cho-
lesterol crystal embolism, hypertensive nephroangiosclero-
sis and aging. Although this mixture cannot be reproduced
in animal models, animal models have nonetheless contrib-
uted to better understanding of the relationships between
renal ischemia and renal atrophy. In these experiments the
lesions involve tubules, interstitium and glomeruli, and lead
to fibrosis. However, before fibrosis sets in, the tubular
lesions are reversible, and this notion is important in a
prospective approach to the human disease.
Tubulointerstitial injury. Chronic reduction of renal per-
fusion pressure leads to severe tubular lesions despite
post-stenotic blood pressure on the order of 60 mm Hg
[65]. Atrophic tubules have a small diameter and simplified
epithelium. Abundant proteineaceous casts may occupy
their lumen.
Many possible factors of tubular cell injury have been
evoked [63], but they were inferred from analogy with acute
post-ischemic renal injury [66]. In fact, tubular changes of
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chronic ischemia might be considered an adaptive change
to hypoperfusion. Gobe´, Axelsen and Searle studied the
cellular events related to unilateral renal artery stenosis in
the rat [67]. The kidney underwent progressive atrophy,
with compensatory increase in weight of the contralateral
kidney. During the initial phase (2 to 5 days) tubular cell
death resulted from both necrosis and apoptosis, whereas
nuclear [3H]thymidine uptake showed increased labeling
and mitosis, providing evidence of epithelial repair. During
the chronic phase (10 to 20 days) renal atrophy progressed
and cell death proceeded from apoptosis alone. After
reversal of renal artery stenosis or nephrectomy of the
nonstenotic hypertrophied kidney, evidence of regenera-
tion consisting of both hypertrophy and hyperplasia was
found. Gobe´ et al hypothesized that the stenotic kidney is
deprived of “renotropin,” the factor inducing compensa-
tory renal growth, but also that whether or not the stenotic
influence remains, this factor is capable of inducing renal
regeneration and regrowth. Other experiments raised the
provocative, although controversial, hypothesis that renal
tubular ischemia triggers a form of autoimmune interstitial
nephritis [68].
From a prospective standpoint, these experiments con-
tain elements of practical interest regarding treatment.
They imply that, rather than leading to passive shrinking of
the kidney, chronic ischemia is a dynamic process, compris-
ing not only an adaptation to reduced blood flow but also a
vigorous potential for tubular cell regeneration. Seven
reports totaling 352 patients showed that revascularization
led to renal function improvement in 55%, stabilization in
31% and worsening in only 14% [69]. This suggests that
revascularization of the chronically ischemic kidney may
not only be beneficial by increasing renal blood flow and
glomerular filtration rate, but may conceivably be followed
by tubular regeneration in about half of the cases. These
data plead for an affirmative policy regarding revascular-
ization of the atherosclerotic human kidney.
Is there anything new on the catastrophic issue of
cholesterol crystal embolism?
Renal cholesterol embolism has become a dreaded compli-
cation of vascular surgery, aortic angiography, transluminal
angioplasty and anticoagulant/thrombolytic treatments [70].
Spontaneous renal cholesterol embolism is also commonly
discovered on biopsy or at autopsy [71, 72].
The clinical picture and the dire prognosis of cholesterol
embolism have been amply described over the last years
[70, 73]. We shall rather focus on two recent developments,
one involving histology and the other management. In a
recent paper 24 patients with cholesterol embolism were
evaluated clinically and histologically [74]. Eight had ne-
phrotic range proteinuria. Light and ultrastructural study
disclosed typical focal segmental or global glomeruloscle-
rosis (FSGS) with podocyte hypertrophy, indicating that
FSGS can be a presenting feature of renal cholesterol
embolism and that cholesterol embolism should be consid-
ered in the differential diagnosis of nephrotic syndrome in
patients with advanced atherosclerosis and renal failure.
Most published series emphasize the catastrophic prog-
nosis of cholesterol embolism. However, a recent publica-
tion indicates that meticulous care and an affirmative
therapeutic protocol may significantly reduce mortality
[75]. Sixty-seven patients were followed up to 74 months
after diagnosis of multivisceral cholesterol embolism with
acute renal failure. The regimen consisted of immediately
withdrawing any anticoagulants, postponing cardiac or vas-
cular surgery and retrograde aortic catheterization, lower-
ing blood pressure below 140/80 mm Hg, treating cardiac
incompetence with vasodilators and hemofiltration, ensur-
ing adequate nutritional support and carrying out bilateral
iliac artery ligation and axillo-bifemoral bypass when lower
limb cholesterol crystal embolism persisted. In-hospital
mortality was 16%. Patient survival at one, two, three and
four years was 74%, 68%, 60% and 51%. At the end point,
36 patients were free from hemodialysis. Thus, this thera-
peutic schedule reduced first-year mortality to 26%, which
compares favorably to the 76% reported in the literature
[70].
ISCHEMIA AS THE FIRST SIGNAL OF RENAL
FIBROSIS
Interstitial fibrosis with severe tubular lesions is a constant
feature of nephroangiosclerosis. More generally, tubuloin-
terstitial damage is the best prognostic factor in all ne-
phropathies, irrespective of the initial injury [76–78]. As
discussed below, most of primary renal diseases compli-
cated with fibrosis are also accompanied by renal vascular
lesions, with or without hypertension. The common denom-
inator of tubulointerstitial injury and fibrosis has long been
considered to be ischemia. This is the case in the pyelone-
phritic kidney [79], in post-obstructive nephropathy [80–
82] and in cyclosporine nephrotoxicity [83–88].
In patients with various types of glomerulonephritis,
Bohle et al found an inverse relationship between intersti-
tial fibrosis and the number and surface area of intertubular
capillaries, and inferred that interstitial fibrosis progres-
sively wastes the number of, and reduces blood flow in
peritubular capillaries [77]. Sclerosis following pyelone-
phritis is also explained by early changes in the intertubular
capillary bed [79]. The pathophysiology of this destructive
process has recently stimulated intense interest.
Ischemia should be considered the first of many fibro-
genic signals that sets off a cascade of cellular and molec-
ular responses eliciting extracellular matrix build up. Some
points specifically relevant to renovasculopathies are worth
examining.
In patients with atherosclerotic renal artery stenosis,
curtailment of blood supply to the kidney does not induce
atrophy and fibrosis simply by the lack of red cell and
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oxygen delivery. The earliest consequence of renal under-
perfusion consists of a marked increase in renin production
by the juxtaglomerular apparatus, with proportional gener-
ation of Ang II. Ang II, endothelin-1, transforming growth
factor-b (TGF-b) and platelet-derived growth factor-B
(PDGF-B) are associated culprits in fibrosis [reviewed in
76]. Ang II fosters secretion of endothelin-1 in cultured
mesangial cells [89], and renal vasoconstriction induced by
endothelin-1 is linked to Ang II [90]. Ang II increases the
expression of the TGF-b gene [81, 91–94] and of interstitial
PDGF B-chain mRNA [25], thus contributing to the build
up of extracellular matrix, and especially collagen IV in the
renal interstitium. Thus, although ACE inhibitors decrease
the GFR out of proportion to blood flow in the poststenotic
kidney [95], they are considered to be major antifibrotic as
well as antihypertensive agents [96].
Data concerning benign nephroangiosclerosis are fewer
than those regarding renal artery stenosis, although it was
shown that the juxtaglomerular apparatus is hyperplastic in
renal biopsies from patients with essential hypertension
[97] and that transcription of the angiotensin 1 (AT1)
receptor mRNA in spontaneously hypertensive rats is
enhanced with the progression of nephroangiosclerosis
[98]. The ischemic kidney produces and contains large
amounts of renin [99], with proportional generation of Ang
II, a major factor of renal tissue injury and fibrosis [100].
Johnson et al slowly infused Ang II in rats for 14 days,
which resulted in moderate hypertension and proliferation
of smooth muscle cells, focal tubulointerstitial injury with
tubular atrophy and dilation, interstitial monocytic infil-
trate, and interstitial fibrosis with increased type IV colla-
gen deposition [25]. PDGF B-chain mRNA was localized
by in situ hybridization in the areas of interstitial injury,
which was associated with tubular cell proliferation. Renal
interstitial cells underwent phenotypic modulation in which
they expressed a-smooth muscle actin (a-SMA). However,
this is not the end of the story, as it was more recently
shown that Ang II up-regulates TGF-b1 expression in
fibroblasts [76], and there is experimental evidence that
ACE inhibitors or losartan decrease TGF-b1 and collagen
IV in the renal interstitium [101]. The protective effect of
ACE inhibitors on the development of chronic renal insuf-
ficiency has been established [96], notably in patients with a
clinical diagnosis of nephroangiosclerosis [102, 103]. No
renal biopsies were done to correlate clinical and histolog-
ical findings. Nevertheless, a host of experimental data
points to ACE inhibitors as having definite activity for
limiting interstitial fibrosis in various experimental models
[104], and it seems likely that this is the case for the fibrotic
component of nephroangiosclerosis.
The role of myofibroblasts in interstitial fibrosis has
received much attention of late. This has been studied in
diabetic nephropathy [105] and in the progression of IgA
nephropathy [106, 107]. Immunoperoxidase staining for
a-SMA, a marker of myofibroblasts, was significantly cor-
related with collagen III staining. The increase in cortical
interstitial fractional area was accompanied by a significant
increase in vascular sclerosis and a reduction in the abso-
lute number of small arteries in the interstitium. The nature
of this association between myofibroblasts and interstitial
fibrous tissue is not clear at this point.
Finally, Pichler et al observed that SPARC (Secreted
Protein Acidic and Rich in Cysteine) is expressed by
myofibroblasts in various rat models of nephropathy, in-
cluding cyclosporine A (CsA) nephropathy and Ang II
infusion [108]. SPARC colocalized and correlated with
interstitial type I collagen deposition, and was expressed in
the injured blood vessels of Ang II infused rats. This
suggests a role for SPARC in myofibroblast induced inter-
stitial fibrosis. The observations of Pichler and coauthors
were complemented by Wu et al, who showed SPARC gene
overexpression in a rat model of subtotal nephrectomy that
induced systemic hypertension along with tubulointerstitial
damage and fibrosis [109]. The ACE inhibitor, ramipril,
and the AT1 antagonist, valsartan, ameliorated renal injury
while SPARC overexpression was significantly reduced.
FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND
RENOVASCULOPATHIES
Focal segmental glomerulosclerosis (FSGS) is a glomerular
lesion observed in a wide variety of renal diseases [110,
111]. The initial event triggering FSGS is nonspecific injury
to the glomerular visceral epithelial cell [112, 113]. In rat
experiments based on nephron mass reduction [111, 114]
and also in some forms of secondary FSGS in the human,
FSGS proceeds from glomerular hyperfiltration and in-
creased glomerular intracapillary pressure which exert trac-
tion on the podocytes. They detach from peripheral capil-
laries and the denuded basement membrane facing
Bowman’s capsule becomes the nidus for further develop-
ment of segmental sclerosis [115]. However, hyperfiltration
is not the exclusive mechanism of FSGS, as shown in rats
rendered nephrotic by adriamycin or by puromycin amino-
nucleoside [116]. In fact, the well established concept of
hyperfiltration-induced FSGS has obscured the fact that,
conversely, ischemia is a possible cause of FSGS.
In humans it has long been known that benign nephroan-
giosclerosis leads to two distinct lesions, FSGS and isch-
emic glomerular collapse, both of which may induce com-
plete obsolescence (Fig. 3) [7, 117]. A recent study by Fogo
et al [13] on the renal lesions in African-Americans with
nephroangiosclerosis illustrated this association of global
and of focal sclerosis, which did not correlate with the
degree of renal vascular lesions.
That renal ischemia can indeed be responsible for induc-
ing FSGS was also suggested by two recent studies dealing
with the complications of atherosclerosis. Greenberg et al
reviewed the clinical features and histological findings of 24
patients with cholesterol atheroembolic renal disease [74].
FSGS was observed in 63% of the biopsy specimens. The
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renal changes produced by cholesterol emboli were directly
related to their size, quantity and chronicity. The glomer-
ular lesions consisted of segmental collapse with prominent
reactive podocyte hypertrophy and proliferation, typical of
the “cellular” variant of FSGS [112]. In some glomeruli
FSGS consisted of segmental areas of sclerosis and adhe-
sion to Bowman’s capsule, without significant podocyte
prominence (Fig. 4).
It could be argued that in cholesterol embolism ischemia
in some areas of the kidney was compensated by hyperfil-
tration in groups of glomeruli that are under control of
other, upstream, patent arteries, as discussed 10 years ago
by Oguma [118]. However, the notion that FSGS can also
be observed in atherosclerotic renal artery stenosis is less
readily explained by mechanisms other than ischemia. In
1984, Gephardt et al reviewed 27 cases of FSGS and
identified two patients older than 50 years with atheroscle-
rotic renal disease and nephrotic-range proteinuria. [119]
In one, having unilateral renal artery stenosis, FSGS was
found in both ipsilateral and contralateral kidneys; in the
second, FSGS was present in the ipsilateral kidney. Re-
cently, Thadhani et al analyzed 59 cases of biopsy-proven
FSGS, with 8 of the older patients having documented
severe atherosclerotic renovascular disease [120]. None
had a history of malignant hypertension. Proteinuria was
abundant, but the lack of hypoalbuminemia and of edema
argued against primary nephrotic FSGS. Light microscopy
showed focal segmental tuft collapse and synechiae. All
lesions examined were in kidneys ipsilateral to a stenotic
renal artery. Thadhani and coauthors attributed these
lesions to hyperfiltration, although they occurred in a
situation in which filtration pressure might logically be
expected to be reduced.
How ischemia might induce FSGS is not clear. Of two
diametrically opposed explanations, the first is that isch-
emia within a collapsed glomerular tuft might represent an
insult to podocyte viability and/or anchorage to the GBM.
Conversely, renal ischemia leads to marked vasoconstric-
tion of the glomerular efferent arteriole with tuft expan-
sion, which should logically exert physical traction on the
podocytes, a mechanism of FSGS defended by Kriz et al
[113].
It should also be remembered that the ischemic kidney
generates large amounts of Ang II, which might contribute
to inducing FSGS. Miller, Rennke and Meyer reported that
in rats long-term infusions of Ang II over an eight week
period results in FSGS [121]. In Johnson et al’s protocol on
the effects of chronic Ang II infusion, occasional glomeruli
showed features of segmental hyalinosis and the podocytes
had a marked increase in desmin content [25]. These data
are compatible with the notion that increased generation of
Ang II in the ischemic kidney may induce podocytic
changes and FSGS.
The thesis that ischemia is a major mechanism of FSGS
in renal artery stenosis and cholesterol embolism does not
obviate other contributing factors. It is worth recalling that
Kasiske, in a large autopsy study, found a significant
correlation between the number of sclerotic glomeruli and
the extent of atherosclerotic lesions within the rest of the
body [122]. Also, Diamond and Karnovsky presented a
body of arguments suggesting common pathways between
FSGS and atherosclerosis, in particular abnormalities in
lipid metabolism playing a central role in the progression of
glomerular injury to FSGS [123]. Further studies, especially
centered on the pathology of the kidney in conditions
where the blood supply to the kidney is uniformly reduced,
Fig. 3. Glomerulus from a patient with mild hypertension showing the
early stages of hypertensive glomerulosclerosis. The entering afferent
arteriole is somewhat dilated with focal arteriolar hyalinosis. The hilus of
the glomerulus is thickened by an increase in mesangial cells and matrix,
and there is a hyaline deposit at the juncture between arteriole and hilus.
The perihilar mesangium is increased, with thickening of the peripheral
capillary loops in this region with significant capsular adhesions (trichrome
staining, 3270).
Fig. 4. Glomerulus from a patient with renal arterial cholesterol emboli
(box), showing the typical lesions of focal segmental glomerulosclerosis,
with part of the glomerulus showing extensive sclerosis including classical
hyalinosis lesions, while the remainder of the glomerulus is ostensibly
normal (trichrome stain, 3290; in the box, 380).
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might adduce evidence for another, hitherto overlooked
mechanism of FSGS.
RENAL VASCULAR LESIONS IN PRIMARY
NEPHROPATHIES
Renal vascular lesions unexplained by hypertension are
common in nephropathies
Arteriosclerosis and/or arteriolosclerosis in a patient suf-
fering from glomerular or interstitial nephritis were long
considered the consequence of hypertension. Yet it was
known that in Barrter’s syndrome, congenital chloride-rich
diarrhea and chronic laxative addiction, renal histology
consistently shows vascular lesions in the absence of hyper-
tension [73]. Similarly, in scleroderma renal biopsy reveals
renal vascular lesions before the onset of hypertension.
Actually, the prevalence of renal vascular lesions in the
absence of hypertension is unusually high in primarily
nonvascular nephropathies and might play an important
role in the development to chronic renal failure [124, 125].
This has been shown in various glomerulopathies, including
poststreptococcal glomerulonephritis (GN) [126], IgA GN
[127, 128], membranous GN [129], lupus nephropathy and
diabetes [reviewed in 5].
We studied 1450 renal biopsies, focusing on the preva-
lence of vascular lesions according to type of renal disease,
age, blood pressure, and renal function at time of biopsy
[73]. There were 1377 biopsies in patients with evidence of
renal disease and 73 in patients whose biopsy had been
carried out for microscopic hematuria and yielded normal
renal tissue, and who were considered as adequate controls.
Vascular lesions were found in 24.6% of controls, with a
stepwise increase from 6.2% before age 40 to 30.7% in the
40 to 65 age group, and 53.3% after 65. In contrast, vascular
lesions were found in 54.5% of patients with primary
glomerular diseases, with a particularly high prevalence in
IgA GN (51.8%), idiopathic membranous GN (58.2%),
primary FSGS (67.4%), and to a lesser degree in minimal
change disease (39.8%). Early onset of vascular lesions was
especially striking before age 40 in IgA GN (28.3%) and in
FSGS (20.6%). The prevalence was even greater in chronic
interstitial nephritis, where vascular lesions were found in
76.5% of 132 cases, with the same prevalence in hyperten-
sive and normotensive patients.
The study group was divided into two subsets according
to renal function. Renal insufficiency was defined by a
creatinine clearance ,80 ml/min. In patients with primary
glomerular diseases, the prevalence of vascular lesions was
41.1% when renal function was normal, versus 82.1% in
those with renal insufficiency. Conversely, vascular lesions
were not correlated with renal function in patients with
chronic interstitial nephritis (80% vs. 75.2%).
Renal vascular lesions in primary nephropathies are
correlated with progression to renal fibrosis and renal
failure
The renal vascular lesions that we and others [5, 127]
observed in the course of nephropathies consisted essen-
tially of arteriolar hyalinosis associated with arteriosclero-
sis, which are correlated with the development of intersti-
tial sclerosis. Vascular lesions and interstitial fibrosis are
the best prognostic indicators in IgA GN [127, 128], in
which vascular lesions predominating on the afferent arte-
riole precede the onset of hypertension.. The same omi-
nous prognosis of vascular involvement was observed in
lupus nephritis and in the diabetic kidney [5]. Vascular
lesions and interstitial fibrosis are even more severe in
primary FSGS [127], a finding that might explain the
pronounced nephrotoxic potential of CsA in this form of
idiopathic nephrotic syndrome [84].
It has been established that lesions of FSGS occurring in
the course of various glomerulopathies, such as minimal
change disease [130], membranous GN [131, 132], diabetic
nephropathy [133] and IgA GN [134] herald a rapid course
to end-stage renal failure. In these observations no corre-
lations were specifically made to seek a relationship be-
tween renal vascular lesions and FSGS. It would be worth
tackling such a study. This might greatly add to our
understanding of the relationships among vascular lesions,
glomerular ischemia, FSGS and the aggravation of primary
glomerulopathies by superimposed focal segmental sclero-
sis.
CONCLUSIONS AND PERSPECTIVES
Renal ischemia is a component of most renal diseases,
including nephroangiosclerosis, renal artery stenosis, and
renal vascular lesions occurring in the course of glomerular
or interstitial nephropathies. Although the primary mech-
anism of such varied conditions is obviously not univocal,
its common outcome is renal fibrosis followed by atrophy
and chronic renal failure. The foregoing review leaves
many questions unanswered, but also opens countless
prospects.
First, hypertensive nephroangiosclerosis increasingly ap-
pears to be in large part a genetic disease leading unac-
ceptably high numbers of individuals, especially of African
origin, to untimely renal failure and cardiomyopathy. That
renal vascular lesions are part of the genetic processes
leading to, rather than resulting from hypertension is still a
hypothesis, but seems increasingly substantiated by epide-
miologic studies and animal experiments. This concept is
still in its infancy, but its implications in terms of research,
prevention and treatment could be important.
Second, atherosclerotic renal disease is increasingly rec-
ognized as a cause of potentially curable chronic renal
failure, implying a tremendous impact on public health
costs. However, its prevalence is still poorly determined, its
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diagnostic screening is far from routine in populations at
risk, and criteria for time and mode of treatment are not
well defined. Although animal models are far from repro-
ducing the lesions observed in human atheromatous renal
disease, they still provide stimulating notions on the capac-
ity of the ischemic kidney to regenerate, as well as on drug
interventions opposing ischemic fibrosis. The respective
roles of revascularization on the one hand and of Ang II
and endothelin 1 antagonists in arresting renal atrophy,
controlling interstitial fibrosis and promoting tubular re-
generation are some of the issues that should be tackled.
Specific answers to these questions should help define
prevention of end-stage renal disease in elderly patients
whose survival rate on dialysis is disastrous.
Third, that renal vascular lesions unrelated to, although
participating in hypertension are found in the glomerulopa-
thies having the worst prognosis is well established but
poorly understood. This unexplained relationship should be
an incentive to center further research on the renal vessels
as much as on the glomeruli, especially in IgA nephropathy,
idiopathic membranous glomerulopathy and focal segmen-
tal glomerulosclerosis. In all these conditions, it is hardly
conceivable that renal vascular lesions have no bearing on
the glomerular tuft. What is the pathophysiologic link
between renal vessel lesions and glomerular injury? What
are the respective parts played by genetic factors in
nephroangiosclerosis and in the immunologic or metabolic
process creating glomerular injury, and how does this
combination entail a worse prognosis of glomerular dis-
ease? These questions are appropriate and research should
be oriented to answering them. Last but not least, that
ischemia per se is able to induce glomerular focal sclerosis
seems an emerging notion. Confirming and explaining it
would greatly help understand how FSGS leads to acceler-
ated renal compromise in nephroangiosclerosis, in various
glomerulopathies and in the aging kidney.
Fourth, ischemia is a fibrogenic signal. The process is
self-perpetuating, as ischemia promotes fibrosis and fibrosis
aggravates ischemia. The mechanisms of renal fibrosis are
the subject of intense interest, and each new publication
adds a piece to an increasingly complicated puzzle. This
review does not have the pretention to construct a system
centered on renal ischemia as a leading cause of renal
fibrosis. However, our best pharmacologic means of oppos-
ing renal fibrosis are all based on Ang II, and probably
endothelin-1 antagonists, and no one would deny that they
are also anti-ischemic agents, the beneficial effects of which
are not yet fully comprehended.
Renal ischemia is not a terra incognita, but many blanks
are still scattered on the map that open exciting perspec-
tives for imaginative explorers.
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